These included four patients with TNBC (ER and PR negativity defined as Allred score 0 to 3), three of which were invasive cancers of no specific type (IC NST) and one apocrine invasive cancer; and three HER2+ patients with breast cancer (two of which were ER+PR+, and one ER−PR−). This evidence concerns the gene ERBB2 and breast carcinoma.